AU 2014/287422 B2 - Treatment Of Papulopustular Rosacea With Ivermectin - The Lens

Treatment Of Papulopustular Rosacea With Ivermectin

Published: Apr 13, 2017
Earliest Priority: Jul 08 2013
Family: 45
Cited Works: 0
Cited by: 0
Cites: 4
Additional Info: Full text

Abstract

Methods and compositions for safe and effective treatment of papulopustular rosacea in a subject are described. The methods involve topically applying to an affected skin area a topical composition containing ivermectin and a pharmaceutically acceptable carrier. Treatment with ivermectin represents an innovative therapy that is more robust and effective than the conventional treatments.

Claims

A method of treating papulopustular rosacea in a subject in need thereof, comprising topically administering, once daily, to a skin area affected by the papulopustular rosacea a therapeutically effective amount of a pharmaceutical composition comprising ivermectin and a pharmaceutically acceptable carrier, wherein the treatment results in a significant reduction in inflammatory lesion count in the subject as early as two weeks after the initial administration of the pharmaceutical composition.
A method of treating inflammatory lesions of papulopustular rosacea in a subject in need thereof, comprising topically administering, once daily, to a skin area affected by the inflammatory lesions of papulopustular rosacea a pharmaceutical composition comprising ivermectin and a pharmaceutically acceptable carrier, wherein the treatment results in a significant reduction in inflammatory lesion count in the subject as early as two weeks after the initial administration of the pharmaceutical composition.
The method of claim 1 or 2, wherein the subject has moderate to severe papulopustular rosacea before the treatment.
The method of any one of claims 1-3, wherein the subject has 15 or more of the inflammatory lesions before the treatment.
The method of any one of claims 1-4, wherein the pharmaceutical composition comprises about 0.5% to 1.5% by weight ivermectin.
The method of any one of claims 1-5, wherein the pharmaceutical composition comprises about 1% by weight ivermectin.
The method of any one of-claims 1-6, wherein the pharmaceutical composition further comprises one or more ingredients selected from the group consisting of: an oily phase comprising dimethicone, cyclomethicone, isopropyl palmitate and/or isopropyl myristate, the oily phase further comprising fatty substances selected from the group consisting of cetyl alcohol, cetostearyl alcohol, stearyl alcohol, palmitostearic acid, stearic acid and self- emulsifiable wax; at least one surfactant-emulsifier selected from the group consisting of glyceryl/PEG100 stearate, sorbitan monostearate, sorbitan palmitate, Steareth-20, Steareth-2, Steareth-21 and Ceteareth-20; a mixture of solvents and/or propenetrating agents selected from the group consisting of propylene glycol, oleyl alcohol, phenoxyethanol and glyceryl triacetate; one or more gelling agents selected from the group consisting of carbomers, cellulose gelling agents, xanthan gums, aluminum magnesium silicates but excluding aluminum magnesium silicate/titanium dioxide/silica, guar gums, polyacrylamides and modified starches; and water.
The method of any one of claims 1-7, wherein once daily topically administering to the subject the pharmaceutical composition results in a greater reduction in inflammatory lesion count in the subject in comparison to that achieved by topically administering to the subject, twice daily, a second pharmaceutical composition comprising 0.75% by weight metronidazole.
The method of any one of-claims 1-8, wherein once daily topically administering to the subject the pharmaceutical composition results in longer relapse-free time of the inflammatory lesions in the subject in comparison to that achieved by topically administering to the subject, twice daily, a second pharmaceutical composition comprising 0.75% by weight metronidazole.
The method of any one of claims 1-9, wherein the subject is human.
Use of a composition comprising ivermectin and a pharmaceutically acceptable carrier in the manufacture of a medicament for the treatment of papulopustular rosacea in a subject in need thereof to thereby obtain a significant reduction in inflammatory lesion count in the subject as early as two weeks after the initial administration of the medicament, wherein the medicament is to be topically administered, once daily, to a skin area affected by the papulopustular rosacea.
Use of a composition comprising ivermectin and a pharmaceutically acceptable carrier in the manufacture of a medicament for the treatment of inflammatory lesions of papulopustular rosacea in a subject suffering from moderate to severe papulopustular rosacea to thereby obtain a significant reduction in inflammatory lesion count in the subject as early as two weeks after the initial administration of the medicament, wherein the medicament is to be topically administered, once daily, to a skin area affected by the papulopustular rosacea.
The use of claim 11 or claim 12, wherein the composition comprises about 1% by weight ivermectin.